| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: DOVP |
| Security Type |
Common Stock |
| Lead Underwriter |
Lehman Brothers CIBC World Markets Inc |
| Days In Registration |
86 |
| Date Filed |
28-Jan-2002 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2008) |
| Industry |
Manufacturing |
| Business Description |
Biotechnology company focused on the discovery, in-licensing, development and commercialization of novel drug candidates for central nervous system, or CNS, and other disorders, including cardiovascular, that involve alterations in neuronal processing |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
14.99M |
| Contact |
- |
| Number of Employees |
- |
|
| Original Filing Information |
| US |
| Shares Filed |
5.0M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
5.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
750.0K |
| File Amount |
$75.0M |
| File Price Range |
$16.00 - $14.00 |
| File Mid Price |
$15.00 |
Current Filing Information
(Amended 24-Apr-2002) |
|
US |
|
Shares Filed |
5.0M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
5.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$80.0M |
| · % Change from Original |
6.67 |
| File Price Range |
$17.00 - $15.00 |
| File Mid Price |
$16.00 |
|
